Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

There are no transmission terms in the subcorpus


Seroprevalence

There are no seroprevalence terms in the subcorpus

    displaying 1 - 3 records in total 3
    records per page




    The global impact of the first Coronavirus Disease MESHD 2019 (COVID-19) pandemic wave on vascular services

    Authors: - Vascular and Endovascular Research Network; Ruth A Benson; Sandip Nandhra

    doi:10.1101/2020.07.16.20153593 Date: 2020-07-17 Source: medRxiv

    Background: The Coronavirus Disease MESHD 2019 (COVID-19) pandemic is having an unprecedented impact on healthcare delivery. This international qualitative study captured the global impact on vascular patient care during the first pandemic wave. Methods: An online structured survey was used to collect regular unit-level data regarding the modification to a wide range of vascular services and treatment pathways on a global scale. Results: The survey commenced on 23rd March 2020 worldwide. Over six weeks, 249 vascular units took part in 53 countries (465 individual responses). Overall, 65% of units stopped carotid surgery for anyone except patients with crescendo symptoms or offered surgery on a case-by-case basis, 25% only intervened for symptomatic aortic aneurysms MESHD aortic aneurysms HP cancelling all elective repairs. For patients with symptomatic peripheral arterial disease MESHD 60% of units moved to an endovascular-first strategy. For patients who had previously undergone endovascular aortic aneurysm MESHD aortic aneurysm HP repair, 31.8% of units stopped all postoperative surveillance. Of those units regularly engaging in multidisciplinary team meetings, 59.5% of units stopped regular meetings and 39.1% had not replaced them. Further, 20% of units did not have formal personal protective equipment (PPE) guidelines in place and 25% reported insufficient PPE availability. Conclusions: The COVID-19 pandemic has had a major impact on vascular services worldwide. There will be a significant vascular disease MESHD burden awaiting screening and intervention after the pandemic.

    Neurological and neuromuscular manifestations MESHD in SARS-CoV-2: Review of Literature and Case Series

    Authors: Robin Warner

    doi:10.21203/rs.3.rs-37519/v1 Date: 2020-06-22 Source: ResearchSquare

    Abstract: Introduction: The 2019 coronavirus, known as SARS-CoV-2 and COVID-19, was named a pandemic by the WHO in March 2020. It binds to the ACE-2 receptor and transmembrane serine protease 2 and is highly virulent. There are many sequelae of this virus, including neurological consequences. We have performed a literature review of the neurological sequelae of COVID-19 with relation to neuroimaging and then present a case series. Case Series: Seven cases were seen by neurology consultants at the Hospital for Special Surgery in New York City between February and May of 2020; 5 met criteria. The majority of these consultations were called for encephalopathy HP. Some had neuroimaging of brain MRI or head CT, which all showed microvascular disease MESHD. One case had prior imaging without microvascular disease MESHD.Summary/Conclusion: It is known that vascular disease MESHD is a risk factor for severe COVID-19 infection MESHD. This case series demonstrates presence of microvascular disease MESHD in patients with encephalopathy HP. We know that microvascular disease MESHD can be a risk factor for toxic metabolic encephalopathy HP. It is unclear if the microvascular disease MESHD was present prior to infection MESHD, although at least one patient had prior imaging without microvascular disease MESHD. More research is needed to determine if COVID-19 infection MESHD can cause vascular disease MESHD. 

    COVID-19 Critical Illness MESHD Pathophysiology Driven by Diffuse Pulmonary Thrombi and Pulmonary Endothelial Dysfunction Responsive to Thrombolysis

    Authors: Hooman D Poor; Corey E. Ventetuolo; Thomas Tolbert; Glen Chun; Gregory Serrao; Amanda Zeidman; Neha S. Dangayach; Jeffrey Olin; Roopa Kohli-Seth; Charles A. Powell

    doi:10.1101/2020.04.17.20057125 Date: 2020-04-21 Source: medRxiv

    Patients with severe COVID-19 disease MESHD have been characterized as having the acute respiratory distress HP syndrome MESHD (ARDS). Critically ill COVID-19 patients have relatively well-preserved lung mechanics despite severe gas exchange abnormalities, a feature not consistent with classical ARDS but more consistent with pulmonary vascular disease MESHD. Patients with severe COVID-19 also demonstrate markedly abnormal coagulation, with elevated D-dimers and higher rates of venous thromboembolism MESHD thromboembolism HP. We present five cases of patients with severe COVID-19 pneumonia MESHD pneumonia HP with severe respiratory failure HP and shock MESHD shock HP, with evidence of markedly elevated dead-space ventilation who received tPA. All showed post treatment immediate improvements in gas exchange and/or hemodynamics. We suspect that severe COVID-19 pneumonia MESHD pneumonia HP causes respiratory failure HP via pulmonary microthrombi and endothelial dysfunction. Treatment for COVID-19 pneumonia MESHD pneumonia HP may warrant anticoagulation for milder cases and thrombolysis for more severe disease MESHD.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.